Praxis SCI Incubate Cohort 2025

Praxis Spinal Cord Institute is excited to announce the cohort of Praxis SCI Incubate, a four-month program geared towards prototype stage projects with an innovation to transform the lives of people living with SCI. The program provides targeted persons with lived experience (PLEX) and research validation and mentorship, as well as access to our commercialization network.

We’re thrilled to welcome DeCell Technologies, GraspAgain, NeuroHagana (translating to “NeuroDefense”) and Tarkka to the program. These innovative startups are dedicated to enhancing care and cure treatments for people with spinal cord injury (SCI), improving quality of life. Throughout the program, they will receive mentorship and networking opportunities to support their growth.

DeCell Technologies is a Canadian regenerative medicine company developing innovative biomaterials to treat chronic and complex wounds. Their flagship product, DermGEN™, is a human-derived decellularized matrix engineered to accelerate healing in wounds that fail to respond to standard care, including diabetic foot ulcers, burns, and pressure injuries. Unlike traditional grafts, DermGEN™ is gently processed to preserve the tissue’s natural regenerative properties without high-energy sterilization—resulting in a biologically active matrix that supports faster tissue repair and reduces complications. Already in use across multiple Canadian healthcare settings, DermGEN™ is transforming outcomes for clinicians and patients by offering an easy-to-use, effective, and accessible advanced wound care solution.

Visit their website

NeuroHagana translating to “NeuroDefense”, is an innovative biotech company founded on the pioneering research of Dr. Angela Ruban at Tel Aviv University in Israel. They are developing a first-in-class, injectable neuroprotective treatment designed for immediate and simple administration following any type of neurotrauma, regardless of severity. Their solution aims to minimize neurological damage, prevent long-term disabilities, and significantly improve patient outcomes, addressing one of the most critical gaps in emergency medicine.

Visit their website

GraspAgain aims to restore hand function in people with neuromuscular impairments through an intelligent neuroorthosis. The system comprises two main components: a non-invasive brain-machine interface and advanced mechatronics. The brain-machine interface utilizes artificial intelligence to decode biosignals measured from the forearm muscles of the paralyzed hand, accurately interpreting the intended movement. This decoded intention is then mapped to the actuation unit of the orthosis, which executes the corresponding movement. To facilitate daily use, the neuroorthosis consists of two parts: a lightweight hand module and a separate actuation unit. The hand module weighs only 100 grams and fits over the paralyzed hand, while the actuation unit can be easily attached or detached via a smart coupling mechanism as needed. The control system is cable-driven and anatomically inspired; similar to muscles, the motors pull and release “tendons” to generate mechanical movement. Their interdisciplinary team, with extensive expertise, is confident that GraspAgain represents a revolutionary product that will empower people with hand impairments to lead more independent lives.

Visit their website

Tarkka Manufacturing Solutions Inc. is a Canadian medical device company redefining wheelchair seating with the Tetrx™ System — a patent-pending, modular platform made from recyclable carbon fibre. Designed to be individually custom contoured at the point of care- Tetrx™.

Visit their website